Zacks Investment Research lowered shares of Catalent (NYSE:CTLT) from a hold rating to a sell rating in a research note published on Wednesday, December 20th.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
Several other equities analysts have also recently weighed in on the company. Royal Bank of Canada initiated coverage on Catalent in a report on Wednesday, December 13th. They issued an outperform rating and a $46.00 price objective for the company. ValuEngine downgraded shares of Catalent from a buy rating to a hold rating in a research note on Friday, December 1st. BidaskClub downgraded shares of Catalent from a buy rating to a hold rating in a research note on Tuesday, November 14th. Piper Jaffray Companies raised their target price on shares of Catalent from $45.00 to $50.00 and gave the company an overweight rating in a research note on Tuesday, November 7th. Finally, Needham & Company LLC reiterated a hold rating on shares of Catalent in a research note on Monday, October 23rd. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Catalent currently has a consensus rating of Buy and a consensus target price of $44.44.
Shares of Catalent (CTLT) traded up $0.60 during midday trading on Wednesday, hitting $43.00. The stock had a trading volume of 549,834 shares, compared to its average volume of 719,530. The company has a market cap of $5,633.24, a PE ratio of 49.43, a price-to-earnings-growth ratio of 2.69 and a beta of 1.41. The company has a debt-to-equity ratio of 2.01, a current ratio of 2.91 and a quick ratio of 2.49. Catalent has a 12 month low of $25.51 and a 12 month high of $43.39.
Catalent (NYSE:CTLT) last announced its quarterly earnings data on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The company had revenue of $543.90 million during the quarter, compared to analysts’ expectations of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. Catalent’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.16 EPS. sell-side analysts anticipate that Catalent will post 1.47 earnings per share for the current fiscal year.
In other Catalent news, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total transaction of $7,189,365.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Uwe Roehrhoff acquired 7,500 shares of the business’s stock in a transaction on Tuesday, November 21st. The shares were bought at an average price of $39.22 per share, with a total value of $294,150.00. The disclosure for this purchase can be found here. Company insiders own 1.70% of the company’s stock.
A number of hedge funds have recently modified their holdings of CTLT. Janus Henderson Group PLC acquired a new stake in Catalent during the second quarter worth approximately $239,629,000. BlackRock Inc. raised its position in shares of Catalent by 15.2% in the second quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock valued at $614,695,000 after buying an additional 2,316,849 shares in the last quarter. Eagle Asset Management Inc. raised its position in shares of Catalent by 290.9% in the third quarter. Eagle Asset Management Inc. now owns 1,153,710 shares of the company’s stock valued at $47,636,000 after buying an additional 858,600 shares in the last quarter. AJO LP acquired a new stake in shares of Catalent in the second quarter valued at approximately $26,130,000. Finally, Macquarie Group Ltd. raised its position in shares of Catalent by 60.2% in the second quarter. Macquarie Group Ltd. now owns 1,786,764 shares of the company’s stock valued at $62,715,000 after buying an additional 671,429 shares in the last quarter. Hedge funds and other institutional investors own 99.37% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/13/catalent-ctlt-rating-lowered-to-sell-at-zacks-investment-research.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Get a free copy of the Zacks research report on Catalent (CTLT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.